Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astressin 2B is a potent and highly selective peptide antagonist of the corticotropin-releasing factor receptor 2 (CRF2). It exhibits an IC50 of approximately 1.3 nM for CRF2 and greater than 500 nM for CRF1, indicating strong selectivity for the CRF2 subtype[1][3][5][9]. By blocking CRF2 receptors, Astressin 2B antagonizes physiological processes mediated by this receptor—including inhibition of gastric emptying and modulation of stress responses. It has been widely used in preclinical research to dissect the role of CRF signaling in gastrointestinal function, inflammation models (such as colitis), anxiety-related behaviors, and vascular biology[6]. The compound is a synthetic cyclic peptide with several non-natural amino acid modifications to enhance stability and selectivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on astressin 2b.